1. Rodeghiero, F, Stasi, R, Gernsheimer, T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386–2393.
Google Scholar | Crossref | Medline | ISI2. McMillan, R, Bussel, JB, George, JN, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008; 83: 150–154.
Google Scholar | Crossref | Medline3. Provan, D, Arnold, DM, Bussel, JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019; 3: 3780–3817.
Google Scholar | Crossref | Medline4. Trotter, P, Hill, QA. Immune thrombocytopenia: improving quality of life and patient outcomes. Patient Relat Outcome Meas 2018; 9: 369–384.
Google Scholar | Crossref | Medline5. Neunert, C, Terrell, DR, Arnold, DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019; 3: 3829–3866.
Google Scholar | Crossref | Medline6. Arnold, DM. Positioning new treatments in the management of immune thrombocytopenia. Pediatr Blood Cancer 2013; 60(Suppl. 1): S19–S22.
Google Scholar | Crossref | Medline7. Neunert, CE, Cooper, N. Evidence-based management of immune thrombocytopenia: ASH guideline update. Hematology Am Soc Hematol Educ Program 2018; 2018: 568–575.
Google Scholar | Crossref | Medline8. Matzdorff, A, Meyer, O, Ostermann, H, et al. Immune thrombocytopenia – current diagnostics and therapy: recommendations of a Joint Working Group of DGHO, OGHO, SGH, GPOH, and DGTI. Oncol Res Treat 2018; 41(Suppl. 5): 1–30.
Google Scholar | Crossref | Medline9. Mingot-Castellano, ME, Roman, MTA, Fernandez Fuertes, LF, et al. Management of adult patients with primary immune thrombocytopenia (ITP) in clinical practice: a consensus approach of the Spanish ITP Expert Group. Adv Hematol 2019; 2019: 4621416.
Google Scholar | Crossref | Medline10. Cooper, N, Kruse, A, Kruse, C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol 2021; 96: 188–198.
Google Scholar | Crossref | Medline11. Kubasch, AS, Kisro, J, Hessling, J, et al. Disease management of patients with immune thrombocytopenia-results of a representative retrospective survey in Germany. Ann Hematol 2020; 99: 2085–2093.
Google Scholar | Crossref | Medline12. Reid, MM. Chronic idiopathic thrombocytopenic purpura: incidence, treatment, and outcome. Arch Dis Child 1995; 72: 125–128.
Google Scholar | Crossref | Medline13. Stasi, R, Stipa, E, Masi, M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436–442.
Google Scholar | Crossref | Medline | ISI14. Ghanima, W, Godeau, B, Cines, DB, et al. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012; 120: 960–969.
Google Scholar | Crossref | Medline15. Cuker, A. Transitioning patients with immune thrombocytopenia to second-line therapy: challenges and best practices. Am J Hematol 2018; 93: 816–823.
Google Scholar | Crossref | Medline16. Bowdler, AJ. The complete spleen: structure, function and clinical significance. New York: Humana Press, 2001.
Google Scholar17. Chaturvedi, S, Arnold, DM, McCrae, KR. Splenectomy for immune thrombocytopenia: down but not out. Blood 2018; 131: 1172–1182.
Google Scholar | Crossref | Medline18. Lucchini, E, Zaja, F, Bussel, J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019. Haematologica 2019; 104: 1124–1135.
Google Scholar | Crossref | Medline19. Pavord, S, Thachil, J, Hunt, BJ, et al. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol 2020; 189: 1038–1043.
Google Scholar | Crossref | Medline20. Zaja, F, Carpenedo, M, Barate, C, et al. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: real-world recommendations. Blood Rev 2020; 41: 100647.
Google Scholar | Crossref | Medline21. Loblaw, DA, Prestrud, AA, Somerfield, MR, et al. American Society of Clinical Oncology clinical practice guidelines: formal systematic review-based consensus methodology. J Clin Oncol 2012; 30: 3136–3140.
Google Scholar | Crossref | Medline22. Bellizzi, V, Bianchi, S, Bolasco, P, et al. A Delphi consensus panel on nutritional therapy in chronic kidney disease. J Nephrol 2016; 29: 593–602.
Google Scholar | Crossref | Medline23. Blasi, F, Concia, E, Del Prato, B, et al. The most appropriate therapeutic strategy for acute lower respiratory tract infections: a Delphi-based approach. J Chemother 2017; 29: 274–286.
Google Scholar | Crossref | Medline24. Brown, AK, O’Connor, PJ, Roberts, TE, et al. Recommendations for musculoskeletal ultrasonography by rheumatologists: setting global standards for best practice by expert consensus. Arthritis Rheum 2005; 53: 83–92.
Google Scholar | Crossref | Medline25. Mahler, DA, Selecky, PA, Harrod, CG, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest 2010; 137: 674–691.
Google Scholar | Crossref | Medline | ISI26. Zafar, SY, Currow, DC, Cherny, N, et al. Consensus-based standards for best supportive care in clinical trials in advanced cancer. Lancet Oncol 2012; 13: e77–e82.
Google Scholar | Crossref | Medline27. Caplan, A, Fett, N, Rosenbach, M, et al. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol 2017; 76: 1–9.
Google Scholar | Crossref | Medline28. Oray, M, Abu Samra, K, Ebrahimiadib, N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf 2016; 15: 457–465.
Google Scholar | Crossref | Medline29. Rhen, T, Cidlowski, JA. Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med 2005; 353: 1711–1723.
Google Scholar | Crossref | Medline | ISI30. Schacke, H, Docke, WD, Asadullah, K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23–43.
Google Scholar | Crossref | Medline | ISI31. Bussel, JB, Tkacz, J, Manjelievskaia, J, et al. Long-term overuse of corticosteroids in patients with immune thrombocytopenia: a real-world analysis of a US Claims Database. In: Poster presented at ASH 2020, 5–8 December 2020, https://ash.confex.com/ash/2020/webprogram/Paper133757.html
Google Scholar32. Al-Samkari, H, Kuter, DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol 2019; 10: 2040620719841735.
Google Scholar | SAGE Journals | ISI33. Kuter, DJ, Tarantino, MD, Lawrence, T. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. Blood Rev 2021; 49: 100811.
Google Scholar | Crossref | Medline34. Cervinek, L, Mayer, J, Doubek, M. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Int J Hematol 2015; 102: 7–11.
Google Scholar | Crossref | Medline35. Lucchini, E, Palandri, F, Volpetti, S, et al. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. Br J Haematol 2021; 193: 386–396.
Google Scholar | Crossref | Medline36. Cooper, N, Hill, QA, Grainger, J, et al. Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified Delphi panel. Acta Haematol 2021; 144: 418–426.
Google Scholar | Crossref | Medline37. Newland, A, Bussel, JB, Bird, R, et al. Predictors of remission in adults with immune thrombocytopenia treated with romiplostim. Blood 2018; 132: 735–735.
Google Scholar | Crossref | Medline38. Ghadaki, B, Nazi, I, Kelton, JG, et al. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 2013; 53: 2807–2812.
Google Scholar | Crossref | Medline39. Gonzalez-Lopez, TJ, Pascual, C, Alvarez-Roman, MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 2015; 90: E40–E43.
Google Scholar | Crossref | Medline40. Mahevas, M, Fain, O, Ebbo, M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol 2014; 165: 865–869.
Google Scholar | Crossref | Medline41. Marshall, AL, Scarpone, R, De Greef, M, et al. Remissions after long-term use of romiplostim for immune thrombocytopenia. Haematologica 2016; 101: e476–e478.
Google Scholar | Crossref | Medline42. Bussel, JB, Wang, X, Lopez, A, et al. Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim. Hematology 2016; 21: 257–262.
Google Scholar | Crossref | Medline43. Carpenedo, M, Cantoni, S, Coccini, V, et al. Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice. Hematol Rep 2015; 7: 5673.
Google Scholar | Crossref | Medline44. Mazzucconi, MG, Santoro, C, Baldacci, E, et al. TPO-RAs in pITP: description of a case series and analysis of predictive factors for response. Eur J Haematol 2017; 98: 242–249.
Google Scholar | Crossref | Medline45. Wong, RSM, Saleh, MN, Khelif, A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 2017; 130: 2527–2536.
Google Scholar | Crossref | Medline46. Gonzalez-Lopez, TJ, Fernandez-Fuertes, F, Hernandez-Rivas, JA, et al. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. Int J Hematol 2017; 106: 508–516.
Google Scholar | Crossref | Medline47. George, JN, Mathias, SD, Go, RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 2009; 144: 409–415.
Google Scholar | Crossref | Medline | ISI48. Khelif, A, Saleh, MN, Salama, A, et al. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: findings from the EXTEND study. Am J Hematol 2019; 94: 200–208.
Google Scholar | Crossref | Medline